Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31


What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries.

Peultier AC, Redekop K, Coche E, Severens JL.

Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):177-189. doi: 10.1080/14737167.2018.1429270. Epub 2018 Feb 5.


Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage.

Paolucci F, Redekop K, Fouda A, Fiorentini G.

Appl Health Econ Health Policy. 2017 Dec;15(6):697-706. doi: 10.1007/s40258-017-0349-3.


Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.

Baranova EV, Verhoef TI, Ragia G, le Cessie S, Asselbergs FW, de Boer A, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group.

J Thromb Haemost. 2017 Mar;15(3):465-472. doi: 10.1111/jth.13615. Epub 2017 Feb 17.


Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.

Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group.

J Thromb Haemost. 2017 Mar;15(3):454-464. doi: 10.1111/jth.13601. Epub 2017 Feb 17.


Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges.

Fugel HJ, Nuijten M, Postma M, Redekop K.

Front Pharmacol. 2016 May 9;7:113. doi: 10.3389/fphar.2016.00113. eCollection 2016.


Cost-effectiveness in Clostridium difficile treatment decision-making.

Nuijten MJ, Keller JJ, Visser CE, Redekop K, Claassen E, Speelman P, Pronk MH.

World J Clin Cases. 2015 Nov 16;3(11):935-41. doi: 10.12998/wjcc.v3.i11.935.


A Cost-Effectiveness Analysis Of Aspirin In The Primary Prevention Of Cardiovascular Diseases And Colorectal Cancer.

Soon S, Chia WJ, Redekop K, Wee HL.

Value Health. 2015 Nov;18(7):A462. doi: 10.1016/j.jval.2015.09.1200. Epub 2015 Oct 20. No abstract available.


Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.

Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH; EU-PACT group; members of the EU-PACT group are.

Thromb Res. 2015 Jul;136(1):94-100. doi: 10.1016/j.thromres.2015.04.034. Epub 2015 May 2.


Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.

Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH; EU-PACT consortium.

Thromb Res. 2015 Jul;136(1):69-75. doi: 10.1016/j.thromres.2015.04.026. Epub 2015 Apr 25.


Noncollapsibility and censoring: what's the bias in estimating effects on survival?

Goossens L, Redekop K, van Gils C.

Epidemiology. 2015 Jan;26(1):e1-2. doi: 10.1097/EDE.0000000000000197. No abstract available.


A randomized trial of genotype-guided dosing of warfarin.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstr├Âm B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group.

N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.


A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.

Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group.

N Engl J Med. 2013 Dec 12;369(24):2304-12. doi: 10.1056/NEJMoa1311388. Epub 2013 Nov 19.



Westwood ME, Raatz HD, Misso K, Burgers L, Redekop K, Lhachimi SK, Armstrong N, Kleijnen J.

Radiology. 2013 Sep;268(3):924-3. No abstract available.


Current methodological issues in the economic assessment of personalized medicine.

Annemans L, Redekop K, Payne K.

Value Health. 2013 Sep-Oct;16(6 Suppl):S20-6. doi: 10.1016/j.jval.2013.06.008.


Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study.

Hoefer IE, Sels JW, Jukema JW, Bergheanu S, Biessen E, McClellan E, Daemen M, Doevendans P, de Groot P, Hillaert M, Horsman S, Ilhan M, Kuiper J, Pijls N, Redekop K, van der Spek P, Stubbs A, van de Veer E, Waltenberger J, van Zonneveld AJ, Pasterkamp G.

Clin Res Cardiol. 2013 Nov;102(11):847-56. doi: 10.1007/s00392-013-0607-9. Epub 2013 Aug 23.


Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.

Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH; EU-PACT Group.

Pharmacogenomics. 2013 Jun;14(8):869-83. doi: 10.2217/pgs.13.74.


OPTImal CArdiac REhabilitation (OPTICARE) following Acute Coronary Syndromes: Rationale and design of a randomised, controlled trial to investigate the benefits of expanded educational and behavioural intervention programs.

Sunamura M, Ter Hoeve N, van den Berg-Emons HJ, Haverkamp M, Redekop K, Geleijnse ML, Stam HJ, Boersma E, van Domburg RT.

Neth Heart J. 2013 Jul;21(7-8):324-30. doi: 10.1007/s12471-013-0422-y.


Commentary: Europe needs a central, transparent, and evidence based regulation process for devices.

Eikermann M, Gluud C, Perleth M, Wild C, Sauerland S, Gutierrez-Ibarluzea I, Antoine SL, Demotes-Mainard J, Neugebauer EA; Signatories of Our Open Letter to the European Union.

BMJ. 2013 May 7;346:f2771. doi: 10.1136/bmj.f2771. No abstract available.


A systematic review and economic evaluation of new-generation computed tomography scanners for imaging in coronary artery disease and congenital heart disease: Somatom Definition Flash, Aquilion ONE, Brilliance iCT and Discovery CT750 HD.

Westwood M, Al M, Burgers L, Redekop K, Lhachimi S, Armstrong N, Raatz H, Misso K, Severens J, Kleijnen J.

Health Technol Assess. 2013;17(9):1-243. doi: 10.3310/hta17090. Review.

Supplemental Content

Loading ...
Support Center